Aethlon Medical Inc key statistics and ratios
In fiscal 2024, Aethlon Medical Inc had return on equity of -117.2%, debt equal to 0.0% of equity and a current ratio of 3.40. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2012Mar 2012 | 2013Mar 2013 | 2014Mar 2014 | 2015Mar 2015 | 2016Mar 2016 | 2017Mar 2017 | 2018Mar 2018 | 2019Mar 2019 | 2020Mar 2020 | 2021Mar 2021 | 2022Mar 2022 | 2023Mar 2023 | 2024Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | −229.1% | −290.7% | −188.2% | −523.7% | −494.6% | <−999% | <−999% | <−999% | −912.0% | <−999% | <−999% | <−999% | — |
| Net margin | −596.6% | −397.7% | −822.6% | −891.5% | −549.6% | <−999% | <−999% | <−999% | −980.3% | <−999% | <−999% | <−999% | — |
| Free-cash-flow margin | −135.6% | −170.6% | −137.6% | −662.3% | −489.4% | −898.4% | <−999% | <−999% | −822.7% | <−999% | <−999% | <−999% | — |
| Return on equity | — | — | — | — | — | — | −166.8% | −144.8% | −107.7% | −83.7% | −78.8% | −75.1% | −117.2% |
| Return on assets | −967.1% | −732.7% | <−999% | −442.0% | −249.2% | −342.0% | −125.1% | −108.0% | −87.9% | −74.9% | −69.2% | −65.2% | −94.8% |
| Asset turnover | 1.62 | 1.84 | 1.48 | 0.50 | 0.45 | 0.18 | 0.03 | 0.04 | 0.09 | 0.06 | 0.02 | 0.03 | — |
| Current ratio | 0.07 | 0.04 | 0.09 | 2.10 | 4.51 | 2.61 | 15.13 | 2.21 | 9.40 | 7.53 | 9.95 | 10.03 | 3.40 |
| Debt to equity | — | — | — | 25.2% | 32.2% | 76.8% | 13.7% | 39.7% | — | 0.5% | 0.0% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | — | — | n/m | n/m | n/m | — | — | — | — | — | — | — | — |
| R&D as % of revenue | — | 117.1% | 92.9% | 134.8% | 88.2% | 171.7% | 391.6% | 390.2% | 142.6% | 314.4% | 795.8% | 478.0% | — |
| Capital spending as % of revenue | 0.1% | 0.0% | 5.9% | 0.0% | 1.0% | 4.2% | 16.6% | 0.0% | 23.3% | 9.1% | 118.7% | 164.2% | — |
| Quarter | 2022 Q1Jun 2021 | 2022 Q2Sept 2021 | 2022 Q3Dec 2021 | 2022 Q4Mar 2022 | 2023 Q1Jun 2022 | 2023 Q2Sept 2022 | 2023 Q3Dec 2022 | 2023 Q4Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% | <−999% | — | — | — | −431.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | — | — | — | −429.6% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | — | — | — | −515.1% |
| Current ratio | 22.58 | 24.19 | 19.83 | 9.95 | 9.66 | 9.76 | 7.46 | 10.03 |
| R&D as % of revenue | 445.3% | 362.4% | >999% | >999% | — | — | — | 107.2% |
Moat
Weak moat
How hard Aethlon Medical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -89.6% of total assets over 10 years.
- Durability 10 / 20
Operating margin has been a median -1197.2%; its worst year was -3542.5%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 8 years, at a median -1452.6% of revenue.
- Discipline 0 / 20
The diluted share count rose 8039.3% over five years; stock-based pay has been a median 129.8% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies